RT Journal Article
SR Electronic
T1 Deep Learning Phenotyping of Tricuspid Regurgitation for Automated High Throughput Assessment of Transthoracic Echocardiography
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.22.24309332
DO 10.1101/2024.06.22.24309332
A1 Vrudhula, Amey
A1 Vukadinovic, Milos
A1 Haeffle, Christiane
A1 Kwan, Alan C.
A1 Berman, Daniel
A1 Liang, David
A1 Siegel, Robert
A1 Cheng, Susan
A1 Ouyang, David
YR 2024
UL http://medrxiv.org/content/early/2024/06/24/2024.06.22.24309332.abstract
AB Background and Aims Diagnosis of tricuspid regurgitation (TR) requires careful expert evaluation. This study developed an automated deep learning pipeline for assessing TR from transthoracic echocardiography.Methods An automated deep learning workflow was developed using 47,312 studies (2,079,898 videos) from Cedars-Sinai Medical Center (CSMC) between 2011 and 2021. The pipeline was tested on a temporally distinct test set of 2,462 studies (108,138 videos) obtained in 2022 at CSMC and a geographically distinct cohort of 5,549 studies (278,377 videos) from Stanford Healthcare (SHC).Results In the CSMC test dataset, the view classifier demonstrated an AUC of 1.000 (0.999 – 1.000) and identified at least one A4C video with colour Doppler across the tricuspid valve in 2,410 of 2,462 studies with a sensitivity of 0.975 (0.968-0.982) and a specificity of 1.000 (1.00-1.000). In the CSMC test cohort, moderate-or-severe TR was detected with an AUC of 0.928 (0.913 - 0.943) and severe TR was detected with an AUC of 0.956 (0.940 - 0.969). In the SHC cohort, the view classifier correctly identified at least one TR colour Doppler video in 5,268 of the 5,549 studies, resulting in an AUC of 0.999 (0.998 – 0.999), a sensitivity of 0.949 (0.944 - 0.955) and specificity of 0.999 (0.999 – 0.999). The AI model detected moderate-or-severe TR with an AUC of 0.951 (0.938 - 0.962) and severe TR with an AUC of 0.980 (0.966 - 0.988).Conclusions We developed an automated pipeline to identify clinically significant TR with excellent performance. This approach carries potential for automated TR detection and stratification for surveillance and screening.Computer Vision Based Tricuspid Regurgitation (TR) Detection: An automated deep learning pipeline was trained to stratify tricuspid regurgitation severity using large-scale data in the form of A4C TTE videos with colour Doppler across the tricuspid valve. The pipeline generalized across two geographically distinct test sets from CSMC and SHC, demonstrating the pipeline’s ability to detect clinically significant TR using single-view TTE videos with Doppler information. These results open the door to potential TR point-of-care screening.Key Question Can an automated deep learning model assess tricuspid regurgitation severity from echocardiography?Key Finding We developed and validated an automated tricuspid regurgitation detection algorithm pipeline across two healthcare systems with high volume echocardiography labs. The algorithm correctly identifies apical-4-chamber view videos with colour Doppler across the tricuspid valve and grades clinically significant TR with strong agreement to expert clinical readers.Take Home message A deep learning pipeline could automate TR screening, facilitating reproducible accurate assessment of TR severity, allowing rapid triage or re-review and expand access in low-resource or primary care settings.Competing Interest StatementD.O. reports research grants R00 HL157421 and R01HL173526 and support from AstraZeneca Alexion, as well as consulting from EchoIQ, Ultromics, Pfizer, and InVision. A.C.K. reports support consulting fees from InVision.Funding StatementAt the time of part of this work, A.V. was a research fellow supported by the Sarnoff Cardiovascular Research Award. D.O. reports research grants R00 HL157421 and R01HL173526 and support from AstraZeneca Alexion, as well as consulting from EchoIQ, Ultromics, Pfizer, and InVision.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards at Cedars-Sinai Medical Center and Stanford Healthcare. Informed consent was waived as the study involved secondary analysis of existing data without patient contact.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe dataset of videos and reports used to train and test EchoNet-TR is not publicly available due to its potentially identifiable nature.